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We report the electron microscopic structure of an a-dystroglycan (a-DG) fragment (DGEKFc4) that contains binding sites for
lymphocytic choriomeningitis virus (LCMV) and the extracellular matrix (ECM) molecule laminin. In electron microscopic images,
DGEKFc4 appears as dumbbell-shaped rods with a length of 7.5 F 0.5 nM and width of 3 F 0.3 nM. The C-terminal human Fc allows
binding of anti-human Fc antibody resulting in formation of immune complexes that preserve a-DG binding to virus. Electron microscopy
shows the antibody binding to near one end of the dumbbell-shaped rods. Because arenaviruses like LCMV or Lassa fever virus (LFV)
generate poor neutralizing antibodies during natural infection or vaccination, we assayed whether the a-DG receptoid bodies generated could
be used as an efficient antibody mimic. However, the receptor body formed by either a-DG fragment alone or complexed to antibody to
human Fc failed to efficiently neutralize virus.
D 2004 Elsevier Inc. All rights reserved.Keywords: Electron microscopy; a-Dystroglycan; LamininIntroduction
The cellular receptor for several strains and variants of
lymphocytic choriomeningitis virus (LCMV), for Lassa
fever virus (LFV), other Old World arenaviruses, and clade
C New World arenaviruses is a-dystroglycan (a-DG) (Cao
et al., 1998; Spiropoulou et al., 2002), the extracellular part
of dystroglycan (DG). DG is a ubiquitously expressed,
versatile cell surface receptor that provides a molecular
link between the extracellular matrix (ECM) and the actin-
based cytoskeleton and plays a critical role in assembly of
basement membranes (Ervasti and Campbell, 1991, 1993;
Henry and Campbell, 1998; Henry et al., 2001; Ibraghi-
mov-Beskrovnaya et al., 1992). Initially encoded as a
single protein, DG is post-translationally processed to form0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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1 These authors contributed equally to the paper.an a-DG subunit that is a peripheral protein, and the
transmembrane subunit h-DG. a-DG undergoes high-affin-
ity interactions with Old World arenaviruses, clade C New
World arenaviruses, and with the ECM proteins laminin-1,
laminin-2, agrin, and perlecan (Cao et al., 1998; Ervasti and
Campbell, 1991, 1993; Gee et al., 1993; Spiropoulou et al.,
2002; Talts et al., 1999). a-DG is noncovalently associated
with the membrane-spanning h-DG unit, which binds to the
cytoskeleton proteins dystrophin and utrophin, as well as
signal transduction molecules. Removal of the intracellular
domain of h-DG or substitution of h-DG with a different
membrane-anchoring domain does not alter virus binding,
entry, or infection (Kunz et al., 2003a), indicating that a-
DG is necessary and sufficient for the function of DG as an
arenavirus receptor.
Recent studies mapped the binding site of LCMV on a-
DG within aa 169–408 (Kunz et al., 2001) and the
binding site for laminin within aa 313–408 (Kanagawa
et al., 2004). Despite the largely overlapping binding sites
for laminin and the virus on a-DG, important biochemical
differences between ECM protein and virus binding were
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carbohydrate structures play an important role in binding
to ECM proteins. A lectin-type binding is demonstrated
by (1) recent structural data, (2) the absolute dependence
of a-DG/ECM protein interactions on divalent cations,
and (3) the extreme sensitivity to chelating agents, en-
hanced salt concentration, and in some cases, low con-
centration of heparin (Andac et al., 1999; Ervasti and
Campbell, 1993; Hohenester et al., 1999; Pall et al.,
1996). Our studies show that LCMV binding to a-DG
is independent of divalent cations, insensitive to chelating
agents and heparin, and is not dependent on a-DG-derived
carbohydrates (Borrow and Oldstone, 1992; Kunz et al.,
2001).
With this information on hand, we generated, expressed,
and purified an a-DG fragment containing both viral and
ECM molecule(s) binding site(s). Our primary purpose was
first to obtain EM structural data and thereafter to obtain
crystallographic data on a-DG alone and on a-DG bound to
its ligands. Here we report the EM structure of the a-DG
fragment that contains binding sites for LCMVand laminin,
and the biochemical characterization of the receptoid body
as a virus binding and neutralizing agent.Results
Construction, expression, and purification of DGEKFc4
Regarding the pivotal role of a-DG as an ECM receptor
in the host and as a receptor for important pathogens, one
of our current aims is to analyze the structure of a-DG by
electron microscopy and subsequently by X-ray crystallog-
raphy. To this end, we constructed the a-DG-Fc fusion
protein DGEKFc4 that contains binding sites for LCMV,
laminin, and other ECM molecules. The cDNA fragment
present in DGEKFc4 codes for aa 1–485 of a-DG,
followed by an enterokinase (EK) cleavage site and the
Fc portion (hinge, CH2, and CH3) of human IgG1 (Fig.
1A). We successfully generated stable transfected HEK293-
based cell lines that allow protein expression in serum-free
high-density suspension cultures. Using this efficient ex-
pression system, we applied the strategy shown in Fig. 1B
for the production and purification of >10 mg of recombi-
nant protein of high purity (Fig. 1C). DGEKFc4 shows an
apparent molecular mass of 80 kDa in SDS-PAGE under
reducing conditions, indicating that the carbohydrate con-
tent of DGEKFc4 is significantly lower than that reported
for a-DG from other sources, most likely due to hypogly-
cosylation of the mucin-related domain of a-DG obtained
from our high-output expression system. Under nonreduc-
ing conditions, DGEKFc4 showed an apparent molecular
mass of 150–160 kDa, corresponding to a dimer (Fig. 1C).
The dimeric nature of DGEKFc4 under physiological
conditions was corroborated by gel filtration experiments,
where the protein appeared as a symmetric single peak at amolecular mass of 150–160 kDa. Our expression system
results in concentrations of 1–2 mg/l of recombinant
protein in crude conditioned supernatant, and the total
yields of the recombinant protein after purification were
routinely 40–50%.
Virus binding of DGEKFc4
To characterize the virus binding properties of
DGEKFc4, we used LCMV clone-13 (cl-13) and LCMV
ARM53b (ARM) as the prototype viruses for binding
studies. We first assessed the binding of DGEKFc4 to
LCMV and compared that with the binding of virus to
native a-DG purified from rabbit skeletal muscle. In order
to use the same assay format for determination of the
binding affinity of DGEKFc4 and native a-DG, a-DG
was biotinylated. We noted that the virus binding properties
were not affected by this modification, as the neutralization
of LCMV cl-13 infection by biotinylated a-DG was found
to be not significantly different from unmodified a-DG
(Fig. 2A). When binding to LCMV ARM and LCMV cl-
13 was tested in an ELISA-format binding assay, half
maximal binding was observed with 0.61 nM biotinylated
a-DG (Fig. 2B) and 17.5 nM DGEKFc4 (Fig. 2C). Binding
to LCMV ARM was not saturable at >20 nM a-DG and
>500 nM DGEKFc4. These data confirm and expand our
earlier observations (Kunz et al., 2001; Sevilla et al., 2000;
Smelt et al., 2001) of specific binding of a-DG to LCMV
cl-13 and LCMVARM with a much higher affinity for the
binding of LCMV cl-13 to a-DG when compared to LCMV
ARM.
Electron microscopic study of the a-DG binding fragment
DGEKFc4
Purified DGEKFc4 was absorbed to carbon-coated grids
and negatively stained with 1% sodium silicotungstate (pH
7). The grids were then examined by EM. Examination of
more than 50 independent DGEKFc4 structures showed
that the majority of units are dumbbell-shaped rods 7.5 F
0.5 nM long and 3 F 0.3 nM wide (Fig. 3). The apparent
differences in the length of the rods may be due to some
heterogeneity in our preparations but also because of
differences in their orientation relative to the electron
beam.
Formation of an a-DG fragment-antibody immune complex
The monoclonal antibody (mAb) GG7, which recognized
the Fc portion of DGEKFc4, was added to form an immune
complex. When complexes of DGEKFc4 and anti-Fc IgG
were formed before addition to the virus, we did not detect a
reduction of virus binding by DGEKFc4 with increasing
molar excesses of anti-Fc IgG (Fig. 4A), indicating that
binding of anti-Fc IgG to the Fc moiety of DGEKFc4 does
not interfere with its virus receptor function. Binding of
Fig. 1. Purification of and EM studies of the DGEKFc4 fragment. (A) Schematic representation of DG and DGEKFc4: The putative N-terminal subdomains,
amino acids 30–160 and 181–316 (white), the mucin-related central domain 317–485 (black), and the C-terminal globular domain 486–653 (gray) of a-DG
are indicated. Amino acids 654–895 represent h-DG with the transmembrane domain (dark box). The EK cleavage site and the human IgG1 Fc part are
indicated. (B) The purification strategy used to obtain the DGEKFc4 fragment. (C) SDS-PAGE of purified DGEKFc4 under nonreducing and reducing
conditions. The position of the monomeric DGEKFc4 (75–80 kDa) and the DGEKFc4 dimer (DGEKFc4) 2 at 150–160 kDa are indicated.
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preformed complex between DGEKFc4 and the virus also did
not affect the binding of DGEKFc4 to the virus (Fig. 4B). Fig.Fig. 2. Binding of DGEKFc4 and biotinylated a-DG to LCMVARM and cl-13. (A)
DG: a-DG purified from rabbit skeletal muscle was biotinylated with the reagent N
LCMVARM (open symbols), and cl-13 (full symbols) were incubated with 0, 1,
a-DG for 2 h on ice. The inoculum was then added to 105 CHOK1 cells cultured in
LCMV infection was assessed by immunofluorescence staining for LCMV NP. On
3). (B) Binding of biotinylated a-DG to LCMVARM and Cl-13: LCMVARM (circ
with 0, 0.1, 0.5, 1, 2, 5, 10, and 20 nM of biotinylated a-DG. Bound biotinylated
reaction using ABTS substrate. OD (405) was recorded in an ELISA reader. Fo
subtracted (meanF SD; n = 3). (C) Binding of DGEKFc4 to LCMVARM and cl-13
plate and incubated with 0, 1, 5, 10, 20, 50, 100, and 200 nM of DGEKFc4. Bou
antibody in a color reaction using ABTS substrate. OD (405) was recorded in an EL
BSA was subtracted (mean F SD; n = 3).4C shows the formation of the DGEKFc4  anti-Fc IgG
immune complex. The EMmicrographs show that mAb GG7
appears to bind near one end of the dumbbell-shaped rods.Blocking of infection of cells with LCMV by biotinylated and unmodified a-
HS-X-biotin. To test for biological activity of biotinylated a-DG, 105 pfu of
2, 5, 10, and 20 nM of either biotinylated (circles) or unmodified (squares)
a M24 plate (MOI = 1) for 45 min. Cells were washed and incubated for 16 h.
e hundred cells were counted and NP-positive cells scored (mean F SD; n =
les) and cl-13 (squares) were immobilized in a microtiter plate and incubated
or a-DG was detected with peroxidase-conjugated streptavidine in a color
r the determination of specific binding, background binding to BSA was
: LCMVARM (circles) and cl-13 (squares) were immobilized in a microtiter
nd DGEKFc4 was detected with peroxidase-conjugated anti-human IgG Fc
ISA reader. For the determination of specific binding, background binding to
Fig. 3. Electron micrograph of negatively stained DGEKFc4. Individual
rods measure 7.5 F 0.5 by 3.0 F 0.3 nm. Scale bars = 50 nm.
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tiful, indicating that each rod has two epitopes for mAb GG7.
The EM images indicate that both epitopes for the GG7Fig. 4. Generation of immune complexes containing DGEKFc4/antibody to huma
DGEKFc4 to LCMV cl-13: 100 nM DGEKFc4 was incubated with the indicated
mixture was added to LCMV cl-13 immobilized in microtiter plates. Bound GG7-
IgG in a color reaction using ABTS substrate as described above. For the determina
SD; n = 3). (B) Binding of mAb GG7 anti-human Fc to the complex formed by LC
and incubated with 100 nMDGEKFc4 for 2 h on ice. Bound DGEKFc4 was incubat
GG7 was detected as in A (meanF SD; n = 3). (C) Electron micrograph of DGEK
the gallery with corresponding diagrams. Closed ring structures can only be forme
indicating dimerization of DGEKFc4. Scale bars = 50 nm.antibody are located at the same end of the rod-like structure,
suggesting the formation of head-to-head dimer. This finding
is consistent with our biochemical characterization (Fig. 1),
which indicates that DGEKFc4 dimerizes via the disulfide
bonds present in the human IgG1 Fc part.
Neither the DGEKFc4 nor DGEKFc4/anti-Fc immune
complex can efficiently neutralize virus infection
As anticipated by the relatively low binding affinity of
DGEKFc4, the molecule inefficiently neutralizes virus
infection. To achieve 50% inhibition of infection, 76.1
nM DGEKFc4 were required (Fig. 5A) as compared to
1.4 nM of native a-DG (Fig. 5B). This >50-fold higher
concentration of DGEKFc4 correlates well with the 30-fold
reduced binding affinity to the virus. In addition to the low
efficiency in neutralization, a significantly higher non-
neutralizable infection was found with DGEKFc4 (20–
25%) when compared to native a-DG (<10%). We then
studied neutralization of LCMV cl-13 infection in different
cell lines by DGEKFc4 or by native a-DG. We found that
DGEKFc4 was unable to prevent LCMV infection in the
four cell lines tested (Fig. 5C). In contrast, native a-DG
neutralized virus at >50-fold lower concentrations than
DGEKFc4 (Fig. 5D).
Our data demonstrate that DGEKFc4 is significantly
less efficient in neutralization of virus infection when
compared with native a-DG (Fig. 5). To increase then Fc. (A) Binding of a complex between monoclonal anti-Fc antibody and
molar ratios of GG7 anti-Fc IgG for 2 h on ice. The anti-Fc IgG-DGEKFc4
DGEKFc4 complex was detected with a peroxidase-conjugated anti-mouse
tion of specific binding, background binding to BSAwas subtracted (meanF
MV cl-13 and DGEKFc4. LCMV cl-13 was immobilized in microtiter plates
ed with increasing concentrations of affinity purified mAb GG7. Bound mAb
Fc4-GG7 IgG complexes. A range of complexes can be seen as illustrated in
d if the DGEKFc4 molecule has more than one epitope for GG7, therefore
Fig. 5. Neutralization of LCMV infection with native a-DG and DGEKFc4. (A) Neutralization of LCMV infection with DGEKFc4: 105 pfu of LCMVARM
(circles) and cl-13 (squares) were incubated with 0, 20, 50, 100, 200, and 500 nM of DGEKFc4 (full symbols) or the nonbinding DGEKFc1 (open symbols) for 2
h on ice. The inoculum was then added to 105 CHOK1 cells cultured in a M24 plate (MOI = 1) for 45 min. Cells were washed and incubated for 16 h. LCMV
infection was assessed by immunofluorescence staining for LCMV NP. One hundred cells were counted and NP-positive cells scored (mean F SD; n = 3). (B)
Neutralization of LCMV infection with a-DG: 105 pfu of LCMVARM (circles) and cl-13 (squares) were incubated with 0, 1, 2, 5, 10, and 20 nM of a-DG (full
symbols) or BSA (open symbols) for 2 h on ice. Infection of CHOK1 cells was then performed as in A (meanF SD; n = 3). (C) Neutralization of LCMV cl-13
infection in different cell types with DGEKFc4 as compared to neutralization with native a-DG in Panel D: 4  104 pfu of LCMV cl-13 were incubated with 0,
20, 50, 100, 200, and 500 nM of DGEKFc4 for 2 h on ice. The inoculum was then added to 4  104 CHOK1 cells, MC57 mouse fibroblasts, 3T6 mouse
fibroblasts, or DG (+/+) mouse embryonic stem cells (mESC) cultured in 8-well LabTeks (MOI = 1) for 45 min. Cells were washed and incubated for 16 h.
LCMV infection was assessed by immunofluorescence staining for LCMV NP. One hundred cells were counted and NP-positive cells scored (mean F SD; n =
3). (D) Neutralization of LCMV cl-13 infection in different cell types with DGEKFc4: 4 104 pfu of LCMV cl-13 were incubated with 0, 1, 2, 5, 10, and 20 nM
of a-DG for 2 h on ice. The inoculum was then added to 4  104 CHOK1 cells, MC57 mouse fibroblasts, 3T6 mouse fibroblasts, or DG (+/+) mouse embryonic
stem cells (mESC) cultured in 8-well LabTeks (MOI = 1) for 45 min. Infection was assessed as in C (mean F SD; n = 3).
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DGEKFc4 with polyclonal anti-Fc antibodies. We expected
that binding of anti-Fc IgGs to virus-bound DGEKFc4 will
increase the size of the neutralizing agent from a single
DGEKFc4 dimer to a larger DGEKFc4–anti-Fc IgG com-
plex. The increased size of the virus binding DGEKFc4–
anti-Fc IgG complex when compared with DGEKFc4 alone
may result in more efficient obstruction of the virus–host
cell interaction, improving the virus neutralization capacity.
For the formation of DGEKFc4–anti-Fc immune com-
plexes, we selected polyclonal anti-human IgG1 Fc anti-
bodies generated in mouse, rabbit, and goat. All anti-
human IgG1 Fc antibodies tested showed high affinity
binding to DGEKFc4 and did not interfere with virus
binding (Fig. 6A). Despite the efficient binding of anti-Fc
IgG to DGEKFc4, the addition of anti-human Fc antibodies
did not enhance the neutralizing potency of DGEKFc4
(Fig. 6B).Discussion
We show the electron microscopic structure of an a-DG
fragment containing binding sites for several of the arena-
viruses as well as the binding site for the extracellular matrix
molecule laminin. The establishment of an efficient expres-
sion system in stable transfected HEK293H cells allowed
the production of milligram amounts of recombinant pro-
tein, suitable for structural analysis.
By electron microscopy, we determined the molecular
dimensions of DGEKFc4, which appeared as dumbbell-
shaped rods with a length of 7.5 F 0.5 nM and a width
of 3 F 0.3 nM.
Analysis of a complex formed by DGEKFc4 and the
monoclonal anti-Fc antibody GG7 showed the antibody
binding near one end of the dumbbell-shaped rods in a ratio
of two antibody molecules to one DGEKFc4. This indicates
the formation of a head-to-head dimer and is in line with our
Fig. 6. Neutralization of LCMV cl-13 and LCMVARM infection with DGEKFc4 combined with polyclonal anti-Fc antibodies. (A) Binding of anti-IgG Fc
antibodies to the DGEKFc4/virus complex: LCMV cl-13 was immobilized in a microtiter plate and incubated 10 Ag/ml DGEKFc4. Bound DGEKFc4 was
incubated with increasing concentrations of polyclonal anti-human IgG1 Fc IgGs generated in mouse, rabbit, and goat. Bound anti-Fc antibodies were detected
with corresponding peroxidase-conjugated secondary antibody in a color reaction using ABTS substrate. OD (405) was recorded in an ELISA reader. For the
determination of specific binding, background binding to BSA was subtracted (mean F SD; n = 3). (B) Neutralization of LCMV infection with DGEKFc4
combined with anti-Fc antibodies: 105 pfu of LCMV cl-13 were incubated with 0, 20, 50, 100, 200, and 500 nM of DGEKFc4 for 2 h on ice. To each sample, a
10-fold molar excess of BSA (squares) or polyclonal anti-human IgG1 Fc from mouse (circles), rabbit (triangles), and goat (diamonds) was added for 45 min at
37 jC. The inoculum was then added to 105 CHOK1 cells cultured in a M24 plate (MOI = 1) for 45 min. Samples containing DGEKFc4 correspond to full
symbols, samples with secondary antibody only to open symbols. Infection was assessed as described above (mean F SD; n = 3). All differences shown are
statistically not significant.
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dumbbell-shaped rod is a DGEKFc4 dimer formed by the
disulfide bonds of the Fc moieties, containing two GG7
epitopes. Further, the DGEKFc4–anti-Fc immune complex
was able to bind virus as efficiently as the DGEKFc
fragment alone, indicating the potential use of the complex
in crystallographic studies.
Antibodies generated during natural infection to LCMV
and LFV show poor neutralizing activity (McCormick and
Fisher-Hoch, 2002; Peters et al., 1987). For that reason, we
explored the use of the DGEKFc4 fragment alone or as an
immune complex with an anti-Fc antibody as a possible
neutralization reagent. DGEKFc alone or when complexed
with anti-Fc antibody failed to act as an effective antiviral
antibody mimic. DGEKFc4 bound LCMV cl-13 at a 30-fold
lower affinity when compared to native a-DG. This signif-icant reduction in binding affinity of DGEKFc4 compared
to native a-DG may be caused by a reduced stability of the
virus binding sites due to hypoglycosylation of the mucin-
related domain or reduced accessibility of the binding sites
for virus and laminin in the DGEKFc4 dimer.
The reduced binding affinity of DGEKFc4 for virus
correlated with its poorer neutralizing capacity, as 50%
neutralization required 50–100 nM of DGEKFc4 when
analyzed on four different cell types. Because effective
neutralization of virus in vivo usually requires over a 100-
fold higher concentration of antibodies than required for
neutralization in vitro (Burton et al., 2001; Parren and
Burton, 2001), it is unlikely that DGEKFc4 will have a
therapeutic in vivo value. The inability to significantly
enhance DGEKFc4 neutralization of virus even in the
presence of the anti-Fc antibody complex suggests that the
S. Kunz et al. / Virology 325 (2004) 207–215 213relative low binding affinity of the DGEKFc4 for the virus
and likely not its size is the limiting factor for successful
neutralization. Thus, procedures to increase the binding
affinity to virus will be required to generate a useful
antibody mimic for treatment of arenavirus infections.Materials and methods
Proteins, antibodies, cell cultures, and viruses
For biotinylation, a-DG, purified from rabbit skeletal
muscle, was dialyzed against reaction buffer (0.1 M
NaHCO3, 100 mM NaCl, pH 8.3) and exposed to 1 mM
NHS-X-biotin (Calbiochem) diluted in cold reaction buffer.
The reagent was applied for 20 min on ice with gentle
shaking, after which free biotin was quenched by adding
glycine, pH 8.0, in a final concentration of 50 mM.
Biotinylated a-DG was dialyzed against PBS and biotiny-
lation verified by Western blot using streptavidine coupled
to peroxidase (Pierce) for detection. Protein concentrations
were determined by the method of Bradford.
Monoclonal antibody (mAb) GG7 (anti-Fc of human
IgG1) was purchased from Sigma and affinity purified by
protein G affinity chromatography. MAb 113 anti-
LCMVNP has been described (Buchmeier et al., 1981).
Polyclonal antibodies against human Fc generated in
mouse, rabbit, and goat were from Jackson Immuno-Re-
search Laboratory (West Grove, PA), and HRP-conjugated
IgG anti-mouse, anti-rabbit, and anti-goat were from Pierce
Chemical Co. (Rockford, IL). HEK293H cells were from
GIBCO BRL (Gaithersburg, MD) and initially maintained
at 37 jC, 5% (v/v) CO2 in DMEM (GIBCO BRL) supple-
mented with 10% (v/v) FCS, 100 units/ml penicillin, and
0.1 mg/ml streptomycin. DG (+/+) embryonic stem cells
(ESC), CHOK1 cells, 3T6, and MC57 mouse fibroblasts
cells were maintained as described (Cao et al., 1998; Kunz
et al., 2003b).
LCMV Armstrong ARM53b (ARM) is a triple plaque-
purified isolate of ARM CA 1371 and purified virus stocks
were produced and their titers determined as described
(Dutko and Oldstone, 1983). LCMV clone-13 is a plaque-
purified variant of ARM53b derived from spleen cells of
an adult BALB/WEHI mouse persistently infected since
birth with ARM53b (Ahmed et al., 1984). Seed stocks of
all viruses were prepared by growth in BHK-21 cells.
Purified virus stocks were produced and virus titers deter-
mined as described (Ahmed et al., 1984; Dutko and
Oldstone, 1983).
Generation, expression, and purification of DGEKFc4
DGEKFc4 contains aa 1–485 of a-DG, followed by the
enterokinase (EK) recognition sequence (DDDDKI) and the
Fc part (hinge, CH2, and CH3) of human IgG1. Using the
expression construct IgG1FcpcDNA3 (Chen et al., 1996),the a-DG-Fc fusion protein DGEKFc4 containing aa 30–
408 of a-DG was made. The cDNA fragment Fdf-DG4EK
was amplified by PCR, digested with SacI and BamHI, and
inserted into human IgG1FcpcDNA3, resulting in the con-






For the generation of stable cell lines producing
DGEKFc4, the expression construct DGEKFc4 pcDNA3,
which contains a neomycin resistance cassette, was linear-
ized and transfected into HEK293H cells using lipofect-
amine (GIBCO BRL). Stable transfectants were selected by
antibiotic treatment using geneticin (G-418 sulfate, GIBCO
BRL). After 3 weeks of selection, colonies of stable trans-
fected cells were isolated, expanded, and tested for trans-
gene expression by Western blot analysis. For each
construct, the 10 lines with strongest expression were
propagated and readapted to serum-free culture conditions
using 293SFMII (GIBCO BRL). All lines tested positive for
transgene expression after 4 weeks in serum-free culture.
Concentrations of DGEKFc4 in the supernatants at maximal
cell densities (1–2  106 cells/ml) were in the range of 1–2
mg/l. The high expressing 293H cell clone DGEKFc4 B32
was expanded and 20 l of supernatant were produced.
Supernatant was filtered (0.22 Am), concentrated, and sub-
jected to protein A affinity chromatography as described
(Kunz et al., 2001). Protein A affinity purified material
showed >90% of purity for the DGEKFc4 dimer as assessed
by SDS-PAGE analysis. Protein A purified fractions of
highest purity were pooled and run over a Superdex 200R
column using FPLC. The protein appeared as a sharp,
symmetric peak at Mr 150–160 kDa. Purest fractions were
pooled and concentrated to 5 mg/ml. Protein concentrations
were determined by the method of Bradford.
Electron microscopy
Samples of DGEKFc4 alone or complexed to mAb GG7
were absorbed to carbon-coated grids and negatively stained
with 1% sodium silicotungstate at pH 7. Samples of
DGEKFc4 and GG7 antibody were initially at concentra-
tions of 1 mg/ml, and serial dilution of each alone or
checkerboard dilution of each while holding one reagent
constant was made to obtain optimal reagents for viewing.
Grids were viewed using a Jeol 1200EX microscope,
operated at 100 kV under minimal dose, accurate defocus
conditions.
Binding of biotinylated a-DG and DGEKFc4 to LCMV
a-DG purified from rabbit skeletal muscle was biotiny-
lated with the reagent NHS-X-biotin as described above. To
test for biological activity of biotinylated a-DG, 105 pfu of
S. Kunz et al. / Virology 325 (2004) 207–215214LCMVARM, and cl-13 were incubated with 0, 1, 2, 5, 10,
and 20 nM of either biotinylated or unmodified a-DG for
2 h on ice. The inoculum was then added to 105 CHOK1
cells cultured in a M24 plate (MOI = 1) for 45 min. Cells
were washed and incubated for 16 h. LCMV infection was
assessed by immunofluorescence staining for LCMVNP as
described (Cao et al., 1998). One hundred cells were
counted and NP-positive cells scored (n = 3 F SD). As
the neutralization of LCMV cl-13 infection of biotinylated
a-DG was found to be not significantly different from
unmodified a-DG, the virus binding properties of a-DG
are apparently not affected by biotinylation. To test binding
to biotinylated a-DG, LCMV ARM and cl-13 were immo-
bilized in microtiter plates and incubated with 0, 0.1, 0.5, 1,
2, 5, 10, and 20 nM of biotinylated a-DG. Bound biotiny-
lated a-DG was detected with peroxidase-conjugated strep-
tavidine in a color reaction using ABTS substrate. OD (405)
was recorded in an ELISA reader. For the determination of
specific binding, background binding to BSA was sub-
tracted. To test binding of DGEKFc4, LCMV ARM and
cl-13 were immobilized in a microtiter plate and incubated
with 0, 1, 5, 10, 20, 50, 100, and 200 nM of DGEKFc4.
Bound DGEKFc4 was detected with peroxidase-conjugated
anti-human IgG Fc antibody in a color reaction as described
above. For the determination of specific binding, back-
ground binding to BSA was subtracted.
To assess the impact of the binding of anti-IgG Fc
antibodies on virus binding of DGEKFc4, LCMV cl-13
was immobilized in microtiter plates and incubated 10 Ag/ml
DGEKFc4 for 2 h on ice. Plates were washed and bound
DGEKFc4 incubated with increasing concentrations of
purified antibodies to human IgG1 Fc. Bound anti-Fc
antibodies were detected with corresponding peroxidase-
conjugated secondary antibody in a color reaction using
ABTS substrate as described above. For the determination
of specific binding, background binding to BSA was
subtracted. To assess the formation of complexes between
mAb GG7 and DGEKFc4 on the virus binding, DGEKFc4
(100 nM) was incubated with increasing molar ratios of
purified GG7 anti-Fc IgG for 2 h on ice before addition to
LCMV cl-13 immobilized in microtiter plates. After sev-
eral wash-steps, bound GG7 was detected with an anti-
mouse IgG secondary antibody conjugated to peroxidase.
Neutralization of LCMV infection with native a-DG and
DGEKFc4
Neutralization of LCMV infection with native a-DG or
DGEKFc4 was performed as described in Cao et al. (1998).
Target cells [CHOK1, 3T6, MC57, and DG (+/+) ESC] were
cultured either in M24 tissue culture plates (105 cells/well)
or in 8-well LabTek tissue culture chamber slides (NUNC)
in a density of 4  104 cells/well. Briefly, LCMVARM or
cl-13 (multiplicity of infection = 1) were incubated with 0,
1, 2, 5, 10, and 20 nM of a-DG or 0, 20, 50, 100, 200, and
500 nM of DGEKFc4 for 2 h on ice. As control proteins, 0,1, 2, 5, 10, and 20 nM BSA or 0, 20, 50, 100, 200 and 500
nM of the nonbinding a-DG-Fc fusion protein DGFc1
(Kunz et al., 2001) were used. The inoculum was added
to the target cells for 45 min at 37 jC, 5% (v/v) CO2. Cells
were washed and incubated for 16 h. LCMV infection was
assessed by immunofluorescence staining for LCMVNP
(Cao et al., 1998). One hundred cells were counted and
NP-positive cells scored. For the neutralization of LCMV
infection with DGEKFc4 combined with anti-Fc antibodies,
LCMV cl-13 was incubated with 0, 20, 50, 100, 200, and
500 nM of DGEKFc4 for 2 h on ice. To each sample, a 10-
fold molar excess of BSA (negative control) or affinity
purified polyclonal anti-human IgG1 Fc from mouse, rabbit,
and goat was added for 45 min at 37 jC. Subsequent
infection of target cell was carried out as described above.Acknowledgments
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